Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Name: Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin
License: Public Domain

Novo Nordisk A/S

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

diabetes type-2-diabetes-mellitus

diabetes, type 2 diabetes mellitus

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 127847
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.